About: COVID-19 in patients with lung cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in patients with lung cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 in patients with lung cancer
Creator	Luo, Jia Greenbaum, Benjamin Lai, W Ng, Kenneth Rudin, Charles Arbour, Kathryn Bandlamudi, Chaitanya Chaft, Jamie Daly, Robert Donoghue, Mark Drilon, Alexander Egger, Jacklynn Eng, Juliana Falcon, Christina Hellmann, Matthew Hoyos, David Iqbal, Afsheen Kris, Mark Li, Bob Lito, Piro Namakydoust, Azadeh Offin, Michael Paik, Paul Preeshagul, Isabel Riely, Gregory Rizvi, Hira Schoenfeld, Adam Yu, Helena Zauderer, Marjorie Mccarthy, Caroline
source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during this pandemic. PATIENTS AND METHODS: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n=102) at a single center from March 12-May 6, 2020. Thresholds of severity were defined a priori as hospitalization, ICU/intubation/DNI (a composite metric of severe disease including ICU stay, intubation and invasive mechanical ventilation, and/or transition to do not intubate [DNI]), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. HLA alleles were inferred from MSK-IMPACT (n=46) and compared to controls with lung cancer and no known non-COVID-19 (n=5166). RESULTS: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer-deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease (Odds ratios for severe COVID-19 2.9, 95% CI 1.07-9.44 comparing the median [23.5 pack-years] to never and 3.87, 95% CI 1.35-9.68, respectively). Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. HLA supertypes were generally similar in mild or severe cases of COVID-19 compared to non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes. CONCLUSION: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1016/j.annonc.2020.06.007
bibo:pmid	32561401
has license	no-cc
sha1sum (hex)	d6c5f76e4e32e14803113ebc625fb80d5c8dd9cf
schema:url	https://doi.org/10.1016/j.annonc.2020.06.007
resource representing a document's title	COVID-19 in patients with lung cancer
has PubMed Central identifier	PMC7297689
has PubMed identifier	32561401
schema:publication	Ann Oncol
resource representing a document's body	covid:d6c5f76e4e32e14803113ebc625fb80d5c8dd9cf#body_text
is schema:about of	named entity 'Memorial Sloan Kettering' named entity 'Health' named entity 'Memorial Sloan Kettering Cancer Center' named entity 'lung cancer' named entity 'hypertension' named entity 'invasive mechanical ventilation' named entity '95% CI' named entity 'heart disease' named entity 'COVID-19' named entity 'COVID-19' named entity 'MSK' named entity 'AstraZeneca' named entity 'descriptive statistics' named entity 'COVID-19' named entity 'COVID-19' named entity 'single center' named entity 'phenotypes' named entity 'M.D' named entity 'Lung cancer' named entity 'chemotherapy' named entity 'HLA-A' named entity 'sample size' named entity 'COVID-19' named entity 'COVID-19' named entity 'T790M' named entity 'HLA-A' named entity 'allele' named entity 'COVID-19' named entity 'control group' named entity 'infection' named entity 'COVID-19' named entity 'lung disease' named entity 'hypertension' named entity 'COVID-19' named entity 'HLA-A' named entity 'COVID-19' named entity 'Roche' named entity 'lung cancer' named entity 'COVID-19' named entity 'inflammatory' named entity 'lung cancer' named entity 'Statistical analyses' named entity 'Fisher's exact test' named entity 'intubation' named entity 'Memorial Sloan Kettering Cancer Center' named entity 'adaptive immune response' named entity 'follow-up' named entity 'COVID-19' named entity 'cancer care' named entity 'COVID-19' named entity 'supplemental oxygen' named entity 'blood tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software